| 前收盘价格 | 1.34 |
| 收盘价格 | 1.37 |
| 成交量 | 35,935,499 |
| 平均成交量 (3个月) | 12,870,252 |
| 市值 | 1,045,679,168 |
| 价格/销量 (P/S) | 4.56 |
| 股市价格/股市净资产 (P/B) | 3.75 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -119.54% |
| 营业利益率 (TTM) | -42.18% |
| 稀释每股收益 (EPS TTM) | -0.210 |
| 季度收入增长率 (YOY) | 12,927.30% |
| 总债务/股东权益 (D/E MRQ) | 45.40% |
| 流动比率 (MRQ) | 7.86 |
| 营业现金流 (OCF TTM) | -204.34 M |
| 杠杆自由现金流 (LFCF TTM) | -142.38 M |
| 资产报酬率 (ROA TTM) | -16.07% |
| 股东权益报酬率 (ROE TTM) | -45.35% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Geron Corporation | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.00 |
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.09% |
| 机构持股比例 | 81.26% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合